The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / U.S. Regulators Sue to Block Anthem-Cigna & Aetna-Humana Mergers

U.S. Regulators Sue to Block Anthem-Cigna & Aetna-Humana Mergers

July 22, 2016 • By Caroline Humer & Carl O'Donnell

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters)—U.S. antitrust officials on Thursday moved to block an unprecedented consolidation of the national health insurance market, filing suit against Anthem Inc.’s proposed purchase of Cigna Corp. and Aetna Inc.’s planned acquisition of Humana Inc.

You Might Also Like
  • U.S. Antitrust Officials Poised to Block Anthem, Aetna Deals
  • U.S. Justice Department Has Concerns about Aetna-Humana Deal
  • California Insurance Commissioner Urges U.S. to Block Anthem-Cigna Deal

The U.S. Department of Justice (DOJ) says the two mergers would reduce competition, raise prices for consumers and stifle innovation if the number of large, national insurers were to fall from five to three.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“We will not hesitate to intervene. We will not shy away from complex cases,” U.S. Attorney General Loretta Lynch told a news conference. “We will protect the interests of the American people.”

The mergers would create an unacceptable risk of higher insurance premiums on the exchanges created under President Barack Obama’s national healthcare reform law, says Principal Deputy Associate Attorney General William Baer, who spearheaded the antitrust reviews. “We have no doubt that these mergers would reduce competition from what it is today.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In the suit against Aetna, the DOJ cited specific concerns about damage to 1.6 million people in 364 counties who are customers of Medicare Advantage, the program that serves older people. It also said there were issues for those individual plans, where the government has been trying to spur competition and keep prices low.

In the suit against the Anthem-Cigna merger, the antitrust regulators said the $45-billion combination would substantially lessen competition in an already consolidated industry, harming millions of Americans, doctors and hospitals.

The DOJ says it was concerned about the impact on the national corporate business, which serves large companies that employ workers around the country and it said has only four competitors.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

It also says there were issues with local business markets, the individual exchanges and the impact that a combined company could have on contracts with doctors.

Aetna and Anthem had proposed asset sales to the regulators, but they did not create strong enough competitors and they did not solve the issues, Baer said.

Cigna says it was currently evaluating its options. It does not believe the transaction would close in 2016, and the earliest it would close would be in 2017, “if at all.”

Aetna and Humana say they plan “to vigorously defend the companies’ pending merger,” which is worth $33 billion.

Eleven states and the District of Colombia joined the DOJ suit against Anthem and Cigna; eight states and DC joined the suit against Aetna and Humana.

There are currently five national health insurers, and the deals would reduce that number to three. The health insurers have argued that the deals would help them lower prices for consumers by expanding their reach at a time when the nation is facing a constant price rise.

Pages: 1 2 | Single Page

Filed Under: Legal, Legislation & Advocacy Tagged With: Aetna Inc., Anthem Inc., Cigna Corp., Department of Justice, Health Insurance, Humana Inc., Legal, merger

You Might Also Like:
  • U.S. Antitrust Officials Poised to Block Anthem, Aetna Deals
  • U.S. Justice Department Has Concerns about Aetna-Humana Deal
  • California Insurance Commissioner Urges U.S. to Block Anthem-Cigna Deal
  • Aetna’s Deal for Humana May Push Up Costs for Seniors

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)